Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses

The cellular activities of amphotericin B (AmB) used as Fungizone were compared with those of AmB complexed to either egg lecithin and glycocholate (Egam) or egg lecithin and deoxycholate (Edam). Under conditions in which leakage of K+ from erythrocytes and cultured L cells treated with Fungizone was almost complete, Egam and Edam containing concentrations of AmB severalfold greater than the concentration of AmB in Fungizone had no effect but retained the ability to decrease the level of retention of K+ in fungal cells. Analysis by absorption and circular dichroism spectroscopy demonstrated that when these formulations containing AmB at concentrations of less than 10(-5) M were added to buffer, the AmB dissociated slowly as monomers from Egam or Edam and dissociated rapidly as a mixture of monomers and self-associated species from Fungizone. We propose that in Egam and Edam, the absence of free AmB in the self-associated form reduces the toxicity of AmB to mammalian cells, whereas the presence of monomeric AmB results in the retention of the antifungal activities of these complexes.

[1]  S. Elberg,et al.  Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles , 1994, Antimicrobial Agents and Chemotherapy.

[2]  G. Lopez-Berestein,et al.  Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins , 1993, Antimicrobial Agents and Chemotherapy.

[3]  A. Bangham Liposomes: realizing their promise. , 1992, Hospital practice.

[4]  P. Legrand,et al.  Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes , 1992, Antimicrobial Agents and Chemotherapy.

[5]  J. Barwicz,et al.  Effects of the aggregation state of amphotericin B on its toxicity to mice , 1992, Antimicrobial Agents and Chemotherapy.

[6]  J. Bolard,et al.  In vitro models for studying toxicity of antifungal agents , 1992, Antimicrobial Agents and Chemotherapy.

[7]  M. C. Popescu,et al.  Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. , 1992, Biochimica et biophysica acta.

[8]  G. Mandell,et al.  Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro , 1992, Antimicrobial Agents and Chemotherapy.

[9]  D. Lasič Mixed micelles in drug delivery , 1992, Nature.

[10]  T. Walsh,et al.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. , 1992, Drugs.

[11]  A. Janoff Lipids, liposomes, and rational drug design. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[12]  D. Lasič,et al.  Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs , 1991 .

[13]  F. Heitz,et al.  One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. , 1991, Biochemistry.

[14]  S. Schreier,et al.  Characterization and time dependence of amphotericin B: deoxycholate aggregation by quasielastic light scattering. , 1991, Journal of pharmaceutical sciences.

[15]  G. Medoff,et al.  Inhibition of Amphotericin B (Fungizone) Toxicity to Cells by Egg Lecithin-Glycocholic Acid Mixed Micelles , 1990, Antimicrobial Agents and Chemotherapy.

[16]  H. Gallis,et al.  Amphotericin B: 30 years of clinical experience. , 1990, Reviews of infectious diseases.

[17]  J. Bolard,et al.  Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations. , 1990, Biochimica et biophysica acta.

[18]  M. Seman,et al.  Interaction of amphotericin B and its N-fructosyl derivative with murine thymocytes: a comparative study using fluorescent membrane probes. , 1989, Biochimica et biophysica acta.

[19]  S. Schreier,et al.  Polydispersity of aggregates formed by the polyene antibiotic amphotericin B and deoxycholate. A spin label study. , 1989, Biochimica et biophysica acta.

[20]  J. Bolard,et al.  Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids , 1989, Antimicrobial Agents and Chemotherapy.

[21]  T. Patterson,et al.  The role of liposomal amphotericin B in the treatment of systemic fungal infections. , 1989, European journal of cancer & clinical oncology.

[22]  G. Lopez-Berestein Liposomes as Carriers of Antifungal Drugs , 1988, Annals of the New York Academy of Sciences.

[23]  J. Bolard,et al.  Circular dichroism for the determination of amphotericin B binding to liposomes. , 1988, Analytical biochemistry.

[24]  G. Medoff,et al.  Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits , 1985, Antimicrobial Agents and Chemotherapy.

[25]  D. Schlessinger,et al.  Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B , 1985, Antimicrobial Agents and Chemotherapy.

[26]  D. Schlessinger,et al.  Stimulatory, permeabilizing, and toxic effects of amphotericin B on L cells , 1984, Antimicrobial Agents and Chemotherapy.

[27]  D. Schlessinger,et al.  Interaction of plasma proteins and lipoproteins with amphotericin B. , 1984, The Journal of infectious diseases.

[28]  L. Gray,et al.  Structure of amphotericin B aggregates based on calculations of optical spectra , 1983 .

[29]  J. Grange,et al.  Structure of amphotericin B aggregates as revealed by UV and CD spectroscopies , 1981 .

[30]  J. Bolard,et al.  Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: lipid state and cholesterol content dependence. , 1980, Biochimica et biophysica acta.